Lundberg; Ante Sven

Patent Applications and Registrations

Patent applications and USPTO patent grants for Lundberg; Ante Sven.The latest application filed is for "materials and methods for treatment of hemoglobinopathies".

Company Profile

23.5.30

Lundberg; Ante Sven - Cambridge MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders Grant 11,427,838 - Lundberg , et al. August 30, 2	2022-08-30
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders Grant 11,407,997 - Lundberg , et al. August 9, 2	2022-08-09
Materials And Methods For Treatment Of Hemoglobinopathies App 20220211874 - Cowan; Chad Albert ; et al.	2022-07-07
Materials and methods for treatment of Duchenne Muscular Dystrophy Grant 11,369,692 - Kabadi , et al. June 28, 2	2022-06-28
Materials And Methods For Treatment Of Spinocerebellar Ataxia Type 1 (sca1) And Other Spinocerebellar Ataxia Type 1 Protein (atxn1) Gene Related Conditions Or Disorders App 20220047722 - LUNDBERG; Ante Sven ; et al.	2022-02-17
Materials And Methods For Treatment Of Hereditary Haemochromatosis App 20220008558 - Bogorad; Roman Lvovitch ; et al.	2022-01-13
Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders Grant 11,174,469 - Lundberg , et al. November 16, 2	2021-11-16
Materials And Methods For Treatment Of Amyotrophic Lateral Sclerosis And/or Frontal Temporal Lobular Degeneration App 20210260219 - Cowan; Chad Albert ; et al.	2021-08-26
Materials and methods for treatment of hereditary haemochromatosis Grant 11,083,799 - Bogorad , et al. August 10, 2	2021-08-10
Materials And Methods For Treatment Of Hemoglobinopathies App 20210180091 - Chakraborty; Tirtha ; et al.	2021-06-17
Crispr-cas9 Modified Cd34+ Human Hematopoietic Stem And Progenitor Cells And Uses Thereof App 20200384033 - Morawa; Ewelina ; et al.	2020-12-10
Materials And Methods For Treatment Of Hemoglobinopathies App 20200330609 - Cowan; Chad Albert ; et al.	2020-10-22
Compositions And Methods For Treatment Of Proprotein Convertase Subtilisin/kexin Type 9 (pcsk9)-related Disorders App 20200248168 - Kind Code	2020-08-06
Materials And Methods For Treatment Of Spinocerebellar Ataxia Type 2 (sca2) And Other Spinocerebellar Ataxia Type 2 Protein (atx App 20200216857 - LUNDBERG; Ante Sven ; et al.	2020-07-09
Compositions And Methods For Gene Editing App 20200157565 - Lundberg; Ante Sven ; et al.	2020-05-21
Materials And Methods For Treatment Of Apolipoprotein C3 (apociii)-related Disorders App 20200123570 - LUNDBERG; Ante Sven ; et al.	2020-04-23
Materials And Methods For Treatment Of Merosin-deficient Cogenital Muscular Dystrophy (mdcmd) And Other Laminin, Alpha 2 (lama2) App 20200095579 - LUNDBERG; Ante Sven ; et al.	2020-03-26
Materials And Methods For Treatment Of Primary Hyperoxaluria Type 1 (ph1) And Other Alanine-glyoxylate Aminotransferase (agxt) G App 20200080082 - Lundberg; Ante Sven ; et al.	2020-03-12
Materials And Methods For Treatment Of Early Onset Parkinson's Disease (park1) And Other Synuclein, Alpha (snca) Gene Related Co App 20200040061 - LUNDBERG; Ante Sven ; et al.	2020-02-06
Materials And Methods For Treatment Of Glycogen Storage Disease Type 1a App 20190382798 - COWAN; Chad Albert ; et al.	2019-12-19
Materials And Methods For Treatment Of Duchenne Muscular Dystrophy App 20190374655 - KABADI; Ami Meda ; et al.	2019-12-12
Materials And Methods For Treatment Of Dystrophic Epidermolysis Bullosa (deb) And Other Collagen Type Vii Alpha 1 Chain (col7a1) App 20190365929 - LUNDBERG; Ante Sven ; et al.	2019-12-05
Materials And Methods For Treatment Of Amyotrophic Lateral Sclerosis (als) And Other Related Disorders App 20190330604 - LUNDBERG; Ante Sven ; et al.	2019-10-31
Materials And Methods For Treatment Of Pain Related Disorders App 20190224340 - Lundberg; Ante Sven ; et al.	2019-07-25
Materials And Methods For Treatment Of Myotonic Dystrophy Type 1 (dm1) And Other Related Disorders App 20190211362 - LUNDBERG; Ante Sven ; et al.	2019-07-11
Materials And Methods For Treatment Of Hemoglobinopathies App 20190201553 - Cowan; Chad Albert ; et al.	2019-07-04
Compositions And Methods For Gene Editing App 20190185849 - Lundberg; Ante Sven ; et al.	2019-06-20
Materials And Methods For Treatment Of Friedreich Ataxia And Other Related Disorders App 20190160186 - Lundberg; Ante Sven ; et al.	2019-05-30
Materials And Methods For Treatment Of Pain Related Disorders App 20190153477 - Lundberg; Ante Sven ; et al.	2019-05-23
Materials And Methods For Treatment Of Severe Combined Immunodeficiency (scid) Or Omenn Syndrome App 20190112353 - YANG; Ying ; et al.	2019-04-18
Materials And Methods For Treatment Of Hereditary Haemochromatosis App 20190076551 - Bogorad; Roman Lvovitch ; et al.	2019-03-14
Novel Family Of Rna-programmable Endonucleases And Their Uses In Genome Editing And Other Applications App 20190048340 - Charpentier; Emmanuelle Marie ; et al.	2019-02-14
Materials And Methods For Treatment Of Severe Combined Immunodeficiency (scid) Or Omenn Syndrome App 20190038771 - CRADICK; Thomas James ; et al.	2019-02-07
Materials And Methods For Treatment Of Alpha-1 Antitrypsin Deficiency App 20190010490 - COWAN; Chad Albert ; et al.	2019-01-10
Materials And Methods For Treatment Of Hemoglobinopathies App 20180273609 - PORTEUS; Matthew Hebden ; et al.	2018-09-27

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.